VERAXA Biotech (NASDAQ: VRXA) has announced a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support the development of its BiTAC pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity. This integration of artificial intelligence into VERAXA’s research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates.
VERAXA’s BiTAC platform represents a novel approach in cancer immunotherapy, using bispecific T-cell engagers to direct the immune system to attack cancer cells. By combining this with AI-driven analytics, the company aims to overcome historical challenges in oncology drug development, where many promising therapies have been limited by toxicity. Ardigen’s expertise in AI and bioinformatics will enable VERAXA to mine vast datasets to identify the most promising dual-target combinations, potentially accelerating the pipeline and increasing the probability of clinical success. The initial focus will be on preclinical and clinical data analysis, with the goal of selecting targets that maximize efficacy while minimizing adverse effects.
This collaboration underscores a broader trend in the pharmaceutical industry toward incorporating AI and machine learning to streamline drug discovery and development. For VERAXA, which was founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), this partnership aligns with its commitment to leveraging cutting-edge technology. The company is rapidly advancing its pipeline of antibody-drug conjugates and proprietary BiTAC formats into clinical development. The integration of AI could be pivotal in selecting the right targets and combinations, potentially reducing the time and cost associated with bringing new cancer therapies to market.
For more information, the full press release is available at https://ibn.fm/GLFg2. Forward-looking statements in this announcement involve risks and uncertainties, and actual results may differ materially. Details on risk factors are available in the company’s filings with the SEC. As VERAXA continues to develop its BiTAC platform, this collaboration with Ardigen represents a strategic move to harness AI for more precise and effective cancer treatments.
